Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies

Aimi Syamima Abdul Manap1, Shantini Vijayabalan2, Priya Madhavan3, Yoke Yin Chia1, Aditya Arya3, Eng Hwa Wong3, Farzana Rizwan3, Umesh Bindal3 and Shajan Koshy3

1School of Biosciences, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia. 2School of Pharmacy, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia. 3School of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia.

ABSTRACT: Alzheimer disease is a neurodegenerative disease that is signified by cognitive decline, memory loss, and erratic behavior. Till date, no cure for Alzheimer exists and the current Alzheimer medications have limited effectiveness. However, herbal medicines may slow down the disease's progression, which may hopefully reduce the number of cases in the years to come. Numerous studies have been done on characterizing the neuroprotective properties from plants belonging to Scrophulariaceae family, particularly Bacopa monnieri and its polyphenolic compounds known as bacosides. This review presents the findings on bacosides in therapeutic plants and their impact on Alzheimer disease pathology. These reports present data on the clinical, cellular activities, phytochemistry, and biological applications that may be used in new drug development for Alzheimer disease.

KEYWORDS: Alzheimer, aging, therapeutic plant, Bacopa monnieri, bacosides

Alzheimer disease (AD) is a devastating, progressive, and irreversible neurodegenerative disorder, which is clinically characterized by the deterioration of memory, disorientation, increased confusion, and other psychological as well as physical manifestations (Figure 1).1 The appearance of extracellular amyloid-beta (Aβ) deposits in senile plaques and the development of intracellular neurofibrillary tangles, reactive microgliosis, and astrogliosis are the primary histopathological characteristics of AD.2 Alzheimer disease primarily affects the elderly,3 is the most common and feared type of dementia, represents 70% of all dementia cases, and is a worldwide epidemic. Bertram et al.4 postulated that in addition to the sporadic form of AD, for which aging is the primary factor, mutations in the amyloid-beta precursor protein (AβPP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) cause autosomal dominant early-onset familial AD. Polidori et al.5 found that genetic and environmental factors, vascular pathology, and other risk factors also play crucial roles in AD pathogenesis.

Due to the lack of effective disease-modifying treatments, findings on pharmacological or nonpharmacological strategies to slow disease progression are of significant importance. In addition, the failure of potential pharmaceuticals in human clinical trials has highlighted the need for research into early AD diagnosis. As synaptic and neuronal loss along with brain shrinkage has already occurred when AD's clinical symptoms appear, current treatments that seek to slow disease progress are more likely to be effective before the onset of AD symptoms, ideally at the earliest preclinical stage. The lack of effective AD treatments and pharmaceuticals has led to the assessment of alternative therapeutics, such as nutraceuticals. For example, many antioxidants may enhance cognitive ability.6–8 Nutraceuticals have an effect on various neurodegenerative diseases as they modulate signaling pathways.9 Nutraceuticals are nutrients, herbs, and dietary supplements that can help in maintaining physical wellbeing, work against various diseases, and ensure a better quality of life. Bacosides from Bacopa monnieri (B monnieri) are examples of valuable therapeutic agents for AD due to their anti-inflammatory, antioxidant, and Aβ aggregation inhibitor properties. This review presents current clinical studies and scientific evidences that document the therapeutic potential of B monnieri extracts (BME) such as bacosides in AD.

Traditional Aspects of B monnieri
According to World Health Organization, traditional medicine is defined as “the sum total of knowledge, skills and practices based on the theories, beliefs and experiences of different cultures that are used to maintain health, as well as to prevent, diagnose, improve or treat physical and mental illnesses.”10 Many population in the developing countries have reverted to the use of traditional plants in maintaining their health and wellbeing.11 In this age where migration has taken a leap, immigrants tend to bring traditional plants from their country of origin to use as supplements. This has caused the promotion of origin to use as supplements.
of such non-native plants in a foreign country, particularly the ones used in Ayurvedic and Chinese traditional medicine. These plants or plant compounds are known as complementary or alternative medicines in non-native countries. Notably, *B. monnieri*, otherwise known as Brahmi and Aindri (Sanskrit) is classified into the Scrophulariaceae family and found throughout the Indian subcontinent in moist soil, humid, and muddy environments. The genus *Bacopa* has 146 aquatic herbal species dispersed throughout the subtropical regions of the globe, including Nepal, India, Sri Lanka, Taiwan, China, and Vietnam, as well as Florida and other US southern regions. Although it can be seen in the United States, these plants are perceived as weeds in rice fields and abundantly grown in wetlands and marshes of warmer districts. As shown in Figure 2, Brahmi is a succulent herb commonly grown in subtropical nations up to 1500 m altitude. Brahmi, which is traditionally known as “medhya rasayana,” which means brain tonic or nootropic, or in Sanskrit word, referring to intellectual, cognition, and rejuvenation because it enhances the brain's cognitive properties, is popular among Ayurveda practitioners, who use it to treat various ailments, (ie, memory loss, inflammation, epilepsy, fever, and asthma).

### Structure and Components of Bacosides

The chemical compound that has neuropharmacological properties and pseudo-jujubogenin moieties, known as aglycone units, is Bacoside A (dammarane-type triterpenoid saponin; Figure 3). This compound is composed of bacopaside III, bacopaside X, bacoside A3, and bacopasaponin C. Through structural similarity analysis, 12 analogues derived from the bacosides have been characterized and various saponin types have been identified as essential ingredients, known as bacopasides I-XII. *Bacopa*’s additional components include apigenin, cucurbitacin, alkaloids brahmine, monnierin, hersaponin, monnierasides I-III, plantain side B, d-mannitol, herpestine, and nicotine. Table 1 shows molecular composition of Bacoside A.
The Neuropharmacological Activity of Bacoside A
Numerous studies suggested that *B. monnieri*’s bioactive components (ie, bacosides) protect the brain against oxidative damage and age-related cognitive deterioration with several mechanisms of action. In addition, bacosides prevent Aβ aggregation and formation of fibrils as well as protect neurons against Aβ-induced toxicity. From high-performance liquid chromatography (HPLC) analysis, the bioactive constituent, bacoside A, was present in the *B. monnieri* extract (BME)-treated rat serum and could directly or indirectly interact with the neurotransmitter systems to improve memory and learning ability. Bacosides present in *B. monnieri* are commonly non-polar glycosides, which enable it to cross the blood-brain barrier (BBB) via simple lipid-mediated passive diffusion. Similarly, the bioavailability in the brain has been affirmed by the radiopharmaceuticals biodistribution. De et al, using an animal model, described BME as being capable of altering the uptake of radioactivity of 99mTc-labeled ethylene dicysteine diethyl ester (99mTc-ECD) and 99mTc-labeled cystine dimethyl ester (99mTc-CDM) in brain and other organs. The results revealed an increased and significant uptake (*P* < .05) of 99mTc-ECD and 99mTc-CDM in brain and other organs after treatment with BME. As BME is a good antioxidant and has cognitive function on human memory, these findings have evaluated pharmacokinetic interactions of BME and suggested that BME can act on the biodistribution of 99mTc-ECD and 99mTc-CDM in specific organs.

Likewise, clinical studies also showed that oral treatment with *B. monnieri* was able to enhance memory in both adults and children. The effects of *B. monnieri* administration on hepatic and intestinal P-glycoprotein (Pgp) as well as Cytochrome 3A (CYP3A) expression levels were examined in Watkins’ studies. According to him, individually, Pgp-mediated efflux and Cytochrome P450 (CYP450)-mediated metabolism play a vital role in modulating the oral bioavailability of corresponding drug. However, *B. monnieri* mediating effects on CYP3A4 and alterations in Pgp were measured according to the mRNA expression level and functional activity in the intestine and liver of male Sprague Dawley (SD) rats after a week of *B. monnieri* administration. The results showed that *B. monnieri* downregulated both intestinal Pgp and CYP3A expression levels, depending on the testosterone hydroxylase catalytic activity in liver and intestine. Further studies also showed that in vivo pharmacokinetic interaction between digoxin (Pgp substrate) and carbamazepine (CYP 3A substrate) along with the administration of *B. monnieri* extract in male SD rats could alter the pharmacokinetics of both Pgp and CYP3A probe drugs. Probe drug is known to lessen both biological and technical risk factors of tracking a particular target to be selective as well as potent to their target. The results showed that treatment with *B. monnieri* and carbamazepine caused a change in the carbamazepine pharmacokinetic profile with a significant increase in Cmax (maximum serum concentration of the drug achieved in the plasma) and AUC (the area under the plasma drug concentration-time curve) (0–∞) as well reduction in CL/F (apparent total clearance of the drug from plasma after oral administration) opposing to the vehicle control rats.

The Role of Other Compounds in BME
CDR1-08
Also known as Synapsa, or KeenMind, a nootropic CDR1-08 is a well-characterized ethanolic extract of *B. monnieri*. Several lines of evidence demonstrated that CDR1-08 significantly enhances the cognitive performance in the elderly and patients with impaired neurological functions as well as healthy human participants. Moreover, bacosides present in the CDR1-08 are nonpolar glycosides, and it can enter the brain by crossing the BBB through lipid-mediated passive diffusion. The biodistribution in brain also has been affirmed by radiopharmaceuticals. Study by Preethi et al investigated whether treatment with the CDR1-08 could change the methylation
status of reelin and brain-derived neurotrophic factor (BDNF) to enhance the memory through the interaction of N-methyl-D-aspartate receptor (NMDAR) with synaptic proteins. Using rat pups as a model in the study, after treatment with CDRI-08/5-azacytidine (80 mg/kg/3.2 mg/kg), their results demonstrate a higher discrimination toward novel objects than with old objects during the testing. They also observed an elevated level of unmethylated DNA in reelin and BDNF-promoted region, which suggested that this mechanism might contribute to the modulation of synaptic plasticity and thus can enhance learning and memory. However, study by Rai et al provide the evidence for the mechanism underlying the role of the CDRI-08 in restoring spatial memory in amnesic mice. In their study, upon daily oral administration of CDRI-08 (200 mg/kg body weight [BW]) to scopolamine-treated amnesic mice for 7 days, the spatial memory was restored, which was found to be related with significant upregulation of the GluN2B (ionotropic glutamate receptors) subunit expression and reduction in the acetylcholinesterase activity in prefrontal cortex as well as hippocampus.

Bacognize*  
The standardized extract of B monnieri (Bacognize) has been shown to improve some aspects of cognitive functions in a 6-month trial in geriatric Alzheimer patients. In this study, all patients who took 300 mg of Bacognize orally twice a day showed a statistically significant improvement in various components of Mini-Mental State Examination Scale (MMSES) including orientation of time, place and person,
attention, and their language ability in terms of reading, writing, and comprehension at the end of trial. Another study refers this extract to be safe and have sustained cognitive effects when used for 12 weeks in healthy older adults.40 Kumar et al had evaluated the effect of Bacognize on memory of 60 medical students with 42 days of administration. This randomized placebo-controlled trial exhibited a significant improvement in the tests relating to the cognitive functions in the participants who had taken 150 mg of Bacognize.41 The poor solubility of Bacognize also has been improved by recent study of Thakkar et al using the inclusion complex of Bacognize (contained 16% bacosides) and β-cyclodextrin prepared in different molar ratios of B monnieri via co-precipitation method. The results revealed that the inclusion of complex at molar ratio of 1:4 can enhance threefold solubility and stability of B monnieri in inclusion complex.42

Mechanisms as a Neuroprotective Agent
The mechanisms that underlie the progression of neuronal degeneration are described in the following sections. Figure 4 illustrates the neuroprotective effects of bacoside from B monnieri from various studies.43–45

Bacosides and Reactive Oxygen Species
Wide studies have reported the role of superoxide anion, hydroxyl radical, hydrogen peroxide, and nitric oxide in the oxidative stress-mediated neurodegeneration in AD.46,47 Neuronal lesions can activate microglia activation, which further generates excessive superoxide radicals.48 Thus, mitochondrial autophagy serves as a vital source of reactive oxygen species (ROS) production.49 As mitochondria functions as both the source and target of toxic ROS, mechanisms by which mitochondrial dysfunction leads to neuron degeneration in AD are believed to be associated with ROS generation, activation of mitochondrial permeability transition, excitotoxicity, impaired production of adenosine triphosphate, and altered calcium homeostasis.50 Various studies have shown an increased level of 4-hydroxynonenal, the byproduct of oxidative stress in the brain of AD patients.51,52 An increased level of lipid peroxidation (LPO) marker has been reported as well.53,54 Besides that, iron-induced oxidative stress, as demonstrated by iron accumulation in the brain of AD, is responsible for neurodegeneration in patients diagnosed with AD.55

Extensive studies have been performed on neuroprotection of B monnieri against ROS. The administration of B monnieri inhibited LPO especially in the hippocampus, prefrontal cortex, and striatum areas of the rat cerebrum.56 As for the rat’s astrocytes, it significantly reduced the harm done by high concentrations of nitric oxide.57 Likewise, different reports recommended that bioactive components from B monnieri can protect the brain against oxidative harm and improve cognitive capability via a few mechanisms.22,23 The enhanced cognitive capability was attributed to the free radical scavenging properties of the bacosides. Superoxide dismutase (SOD), heat shock protein 70 (Hsp70), and cytochrome P450 (CytP450) in the rat’s cerebrum have critical role in both the production of ROS and scavenging activity.58 The detoxification and binding of free radical scavenging metal ions or increasing the antioxidant properties are the mechanisms involved in the neuroprotection from bacosides25,34,58 (Figure 5). It also reduces the formation of lipid peroxides, divalent metals, scavenging ROS, and restraining lipoxygenase action. As results indicated that ROS level had declined when neurons were treated with BME, we propose that it may control the intracellular oxidative stress.25

Figure 4. Neuroprotective effects of bacoside from Bacopa monnieri.
Likewise, in neonatal hypoglycaemia, *B monnieri* has potent neuroprotective capability in reversing the modified dopamine D1 receptor function, BAX (BCL2 Associated X, Apoptosis Regulator), and gene expressions, respectively. Thus, SOD level is lowered, which in turn causes cortical cell death.59

Furthermore, in rat models of neurotoxicity incitation by ibotenic corrosive and colchicine, *B monnieri* indicated a dosage-related intellectual deficiencies.60 Acrolein is an exceptionally active compound shaped as a LPO byproduct and acts as an oxidative stress inducer by framing adducts of cell nucleophilic groups. It demonstrates a significant elevation of acrolein levels in the hippocampus; *B monnieri* extract is accounted to have neuroprotection in human neuroblastoma cell line SK-N-SH against hydrogen peroxide and acrolein-induced toxicity.3 It also protects through ROS scavenging, maintains the mitochondrial membrane integrity, modulates the expression of several redox regulatory proteins, that is, Sirt1 (Sirtuin 1), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), p66Shc (a member of the SHC family of protein adapters), and ERK1/2 (extracellular signal-regulated protein kinases 1 and 2), and protects the cells from oxidative stress. The counter pressure impact of bacosides of *B monnieri* was studied in adult male SD rats. The results portrayed that it is able to de-stress the modulation of SOD, Hsp70, and CytP450 under unfavourable conditions, for example, stress.58

**Synergistic Action of *B monnieri***

The synergistic effects of *B monnieri* have been investigated, providing information on its possible neuropharmacological effects between this herbal medicine and other plant extracts or synthetic drugs. The synergistic action of *B monnieri* (320 mg), l-theanine (100 mg), *Crocus sativus* (30 mg), copper (2 mg), folate (400 µg) with vitamin B (450-9 µg) and vitamin D (25 µg) in a cohort of elderly subjects (1 capsule per day) for 8 weeks of treatment were investigated.66 The results showed a significant improvement of cognitive decline, perceived stress, and depression tested with Mini-Mental State Examination (MMSE), Perceived Stress Questionnaire (PSQ) Index, and Self-Rating Depression Scale (SRDS) scores.

In another study done in an in vivo model, combination of *B monnieri* (100 mg/kg) with rivastigmine (5 mg/kg) showed significant protection against aluminum chloride (AlCl3)-induced plaque and is accompanied by synaptic dysfunction, neuronal deterioration, dementia, and cognitive declination.63

Therefore, it can suggest that Aβ may be directly toxic to neuronal cells and synapses. The previous study showed that extracts containing soluble Aβ aggregates can induce amyloidosis in an animal model that otherwise never develop amyloid plaque.64 Inhibition of Aβ aggregates and assembly is one of the primary therapeutic strategies in AD treatment and prevention. Another study reported a substantial link between the toxic peptide of Aβ with its membrane interaction.43 In their experiment, Aβ42 monomer initially produces oligomeric species that were membrane-active and cytotoxic. It then aggregated into fibrils, which were promoted through interactions with the bilayer interface. However, aggregation of Aβ42 was reduced and its membrane interaction was inhibited following incubation with Bacside A. Figure 6 shows the mechanism of action of bacside on Aβ.43,61

**Bacside A and Beta Amyloid Toxicity**

A significant inhibitory effect of cytotoxicity, fibrillation, and membrane interactions of beta-amyloid (1-42) were observed by preincubation of Bacside A with Aβ42 in SH-SY5Y cell line model.43 Aβ is a peptide that plays a prominent role in AD progression and toxicity. In AD, Aβ assembles into insoluble amyloid fibrils that aggregate in extracellular neuritic or senile

---

Figure 5. The action mechanism of bacoside against ROS induces mitochondrial damage. ROS indicates reactive oxygen species; SOD, superoxide dismutase.

---
memory impairment in rats compared to those treated with AlCl₃ per se. In their study, chronic administration of AlCl₃ caused functional deficits in learning and memory skills, which were tested using the Morris water maze and Elevated Plus Maze (EPM) tasks. However, rats treated with combination of rivastigmine and B. monnieri showed better acquisition and retention latencies compared to groups treated only with AlCl₃, indicating significant protection against AlCl₃-induced deterioration in learning and memory skills. They concluded that B. monnieri and rivastigmine act through synergistic mechanisms to prevent neuronal damage and enhance cholinergic neurotransmission, thus showing better therapeutic effect compared to treatment alone.

Antidementia and anticholinesterase activities in adult male Swiss mice also were studied using combined extracts of B. monnieri and Ginkgo biloba (GB). In this study, anti-dementia activity was tested against scopolamine (3 mg/kg BW)-induced impairment in passive avoidance (PA) test. Their results indicate a significant increase in transfer latency time (TLT) and no transfer response (NTR) after treatment of combined extracts of B. monnieri at 30 mg/kg and GB at 15, 30, and 60 mg/kg for 7 days of administration. All the extracts showed potent effects toward attenuating the effects of dementia.

**In vivo and in vitro Study on Neuroprotective Effects of BME**

Research on neuroprotective effects of BME has been widely studied before by in vivo and in vitro models. Most of the study conducted by in vivo were performed on male Wistar rats and male Swiss albino mice and rats. However, for in vitro study, different cell line models were chosen to study the effect of BME such as PC12, SH-SY5Y, as well as primary cortical neuron cells. Uabundit et al demonstrated protective effects of BME in male Wistar rat model that had been induced with 2 nmol/2 μL ethylcholine aziridinium ion (AF64A). Result showed that 20, 40, and 80 mg/kg BW of BME was able to mitigate the memory impairment and neurodegeneration in the rats by enhancing the escape latency time ($P<.01$) in the Morris water maze test. They also observed that both cholinergic neuron and neuron density reduction were lessened. Other than that, BME administered orally at 40 mg/kg/day for 5 weeks was able to prevent the neurotoxicity in the cerebral cortex of male Wistar rat brain exposed with aluminum chloride (AlCl₃). Research done by Khan et al revealed that BME given orally at 30 mg/kg BW for 2 weeks significantly improved the memory and learning capability in intracerebroventricular-streptozotocin (ICV-STZ)-induced male Wistar rats. Their finding demonstrates the therapeutic efficacy of BME on cognitive impairment and oxidative damage, observed by significant reduction in LPO levels, increased GSH (glutathione) contents, and upregulated antioxidant enzymes activity such as SOD, GST (glutathione S-transferases), CAT (catalase), and GPx (glutathione peroxidase) in the hippocampus infused by ICV-STZ model. On a different study, BME at 100 mg/kg BW for 180 days lessened both the sodium nitrate (NaNO₂) and D-galactose (D-Gal) levels, which improved the BW, memory, and learning skills. B. monnieri extracts also normalized the ATPase system in AD-induced mice. Dwivedi et al
also demonstrate attenuation of Okaidic acid (OKA)-induced memory dysfunction in SD rats treated with BME at 40 and 80 mg/kg BW for 13 days.

Moreover, interesting extensive finding by Rastogi et al revealed the protective effect of bacosides, against the age-associated neurodegeneration and promotion of healthy brain aging in female Wistar rats. In this study, bacosides were administered orally at 200 mg/kg BW for 3 months in middle aged and aged rats, and its impact on the prevention of Senile Dementia of Alzheimer Type (SDAT) was evaluated. Their findings demonstrated that bacosides was found to display significant anti-aging property by preventing the lipofuscin aggregation in the brain cortex of middle-aged and aged rat. Other than that, cholinergic neurotransmission was observed in aged-rat brain cortex, and treatment with bacosides was able to mitigate this age-associated cholinergic degeneration. Based on the potential findings on bacosides, they suggested that bacosides exerted multitargeted pharmacological action by preventing the lipofuscin accumulation, enhancing the synthesis of cholinergic neurotransmitter acetylcholine, modulating the metabolism of monoaminergic neurotransmitters, and inhibiting LPO in the aged rats.74

A previous study also investigated a new nanotechnology approach for the brain delivery of the Bacacide A for the treatment of neurodegenerative disorders using poly-(d, l)-Lactide-co-Glycolide (PLGA) as surfactant. Bacoside-A-loaded PLGA nanoparticles were prepared via oil-in-water (o/w) emulsion solvent evaporation technique. Surface of nanoparticles were modified by coating with polysorbate 80 to enhance the crossing of BBB. The ability of nanoparticles in targeting the brain was evaluated by in vivo studies using Wistar albino rats. Their results suggested that PLGA nano Bacoside A formulation with a size range of 70-200 nm and a relatively low polydispersity index of 0.391 ± 1.2 showed encapsulation efficiency at 57.11% ± 7.11%, with a drug loading capacity of 20.5% ± 1.98%. Scanning electron microscopy (SEM) and X-ray studies also revealed its spherical shape and low crystallinity. This verified that there were no chemical interactions between both polymer and drug molecules. The in vitro study showed a constant pattern with maximum release of 83.04% ± 2.55% in 48 hours, while in vivo study showed a higher brain concentration of Bacoside A (23.94 ± 1.74 µg/g tissues) that implied a significant role of surface-coated nanoparticles on brain targeting. The overall results suggested the efficiency of surface-modified PLGA nanoparticles in delivery of Bacoside A to the brain.75

In vitro study demonstrated that scopolamine induced PC12 cell death was significantly ameliorated by BME pretreatment, and the viability was restored at 85.75% of the control with 100 µg/mL of BME. B monnieri extracts pretreated cells showed a decreased release of lactate dehydrogenase (LDH) up to 22.42% of total as compared with 30% of scopolamine-treated group. B monnieri extracts also found to ameliorate scopolamine effect by downregulating acetylcholinesterase (AChE) and upregulating BDNF as well as muscarinic-1 receptor expression.76 While pretreatment of BME with different doses (2.5-100 µg/mL) for 3 hours in SK-N-SH cells prior to the addition of 200 µM of H2O2, or 15 µM of acrolein can significantly protect against acrolein-induced cytotoxicity. B monnieri extracts also showed to inhibit the generation of intracellular ROS in addition to preserving the mitochondrial membrane potential. B monnieri extracts pretreatment also prevented the modifications caused by the activity of several redox regulated protein.3 Furthermore, Limpeanchob et al revealed the neuroprotective effect of BME against Aβ-induced cell death in primary cortical cultured neuron cells. They found that the cell viability of cultured cortical cells was increased when treated with 100 µg/mL of BME. From their study, they postulated that Brahmi extract can diminish neuronal death induced by Aβ peptide through the suppression of AChE activity. Brahmi extract also exhibited antioxidiant properties in both in vitro and cell-based assays. By using SH-SYSY model, BME at 0.1 to 25 µM significantly reduced neurotoxicity of oxidized low-density lipoprotein (LDL) in a dose-dependent manner as well as suppressed the elevation of cellular AChE activity mediated by oxidized LDL.77 Using the same SH-SYSY model, Bacoside A at 50 µM exerted significant inhibitory effects upon cytotoxicity, fibrillation, and particularly membrane interactions of Aβ (1-42) (Aβ(42)). Table 2 outlines the specific effects of bacosides on various study designs (in vivo and in vitro) of AD.

Clinical Studies in Humans Using BME

Upon the promising neuroprotective effect of B monnieri in in vitro and in vivo studies, numerous clinical studies on human subjects have been performed using B monnieri for cognitive improvement. A clinical study of standardized extract of B monnieri (150 mg) on 60 medical students from Government Medical College, Nagpur, India over a period of 15 days revealed significant improvement in biochemical analyses, that is, significant elevation in serum calcium levels and enhanced memory test.41 Another group of researchers reported that individual doses of B monnieri and Sideritis scardica extracts in 10 mild cognitive impairment subjects from Germany (mean age: 61.88 ± 6.69 years) resulted in improvement in the d2-concentration test.79 However, treatment with B monnieri (2 × 150 mg) for 90 days in 107 participants (between ages 18 and 60 years) in Swinburne University, Australia led to an improved performance in a structural working remembrance task in healthy participants with no history of neurological diseases, gastrointestinal disorders, as well as chronic infections. Above it all, none of the healthy participants took any cognitive-enhancing drugs.80

Besides cognitive improvement, B monnieri can also enhance learning capability. Consumption of B monnieri for 3 months in 76 human subjects between 40 and 65 years of age in University of Wollongong, Australia resulted in significant effects on retention of new information.81 The consistent consumption of
Table 2. Effects of Bacopa monnieri extract (BME) on various study designs of AD.

| Model Use and Study Design | Dose or Frequency | Effect of BME Treatment | References |
|---------------------------|------------------|-------------------------|------------|
| In vivo model             |                  |                         |            |
| Ethylcholine aziridinium ion (AF64A) (2 nmol/2 μL)—ICV-induced male Wistar rats | 20, 40, and 80 mg/kg BW | BME enhanced the escape latency time (P < .01) in the Morris water maze test. Both cholinergic neuron and neuron density reduction were lessened. | Uabundit et al\(^7\) |
| Oral administration of aluminum chloride (AlCl₃; 50 mg/kg, p.o.)—IP-induced male Wistar rats | 40 and 50 mg/kg BW | BME treated significantly prevented the reduction in SOD activity and decreased the lipid peroxides and protein oxidation. Both electron and fluorescence microscopic studies uncovered substantial inhibition of neurotic change and intra-neuronal lipofuscin in the hippocampus CA1 region. | Jyo\(^8\) et al |
| Streptozotocin (STZ) (3 mg/kg, p.o.)—ICV-induced male Wistar rats | 30 mg/kg BW | BME treated improved the memory and learning capability in ICV-STZ rats. BME treated significantly reduced in LPO levels, increase GSH contents and increase the activity of antioxidant enzymes such as SOD GST, CAT and GPx in the hippocampus infused by ICV-STZ model. | Khan et al\(^9\) |
| c-Galactose (120 mg/kg, p.o.) and sodium nitrite (90 mg/kg, p.o.)—IP-induced male Albino mice | 100 mg/kg BW | BME lessened both the NaNO₃ and c-Gal levels, which improved the body weight, memory, and learning skills. BME also normalized the ATPase system in AD-induced mice. | Kunte and Kuna\(^10\) |
| Oleic acid (300 mg/kg, p.o.)—ICV-induced male Sprague Dawley rats | 40 and 80 mg/kg BW | BME treated significantly enhanced the memory-enhanced memory dysfunction in AD rats as appeared by a reduction in path length and latency time. BMI also restored GCLC, HD1, and Nrf2 as well reduced the neuronal loss, oxidative stress and neuroinflammation. | Dwar\(^11\) et al |
| Female Wistar rats: young (2-3 months), middle-aged (17-18 months), aged (≤2-4 months old) | 200 mg/kg BW | BME (bacosides) significantly (P < 0.05) prevents the lipofuscin aggregation in the middle-aged and aged rat brain cortex. Bacosides also enhances the synthesis of cholinergic neurotransmitter acetylcholine, modulates the metabolism of monoaminergic neurotransmitters and inhibits lipid peroxidation in the aged brain rats. | Rastogi et al\(^12\) |
| Adult albino Wistar rats | 20 mg/kg BW | PLGA nano BME formulation with a size range of 70-200 nm and a relatively low polydispersity index of 0.319 ± 1.2 showed that encapsulation efficiency was 57.11% ± 7.11%, with a drug loading capacity of 20.5% ± 1.98%. SEM revealed the PLGA nano particles spherical shape, as well as it appeared to have low crystallinity by X-ray studies. This verified there were no chemical interactions between both polymer and drug molecules. The in vitro study showed a constant pattern with a maximum release of 83.04% ± 2.55% in 48 hours and in vivo study showed high brain concentration of Bacoamide A (25.94 ± 1.74 μg/g tissues), which implied a significant role of surface-coated nanoparticles on brain targeting. | Jose et al\(^13\) |
| Male Swiss albino mice and Wistar rats were used to evaluate nootropic activity and bioavailability studies, respectively. | 40 mg/kg BW | Bacoamphospholipid complex (BPC) portrayed 2 endothermal peaks (80.90°C and 171°C) in DSC studies. BPC treated significantly improved cognitive ability and anti-amnesic activity in aged mice in most memory-related models studied. BPC also retained effective bacosides concentration for a longer period in rat serum. | Halbbu et al\(^14\) |
| Scopolamine—IP-induced male Swiss albino mice | 120 mg/kg BW | BME treated reversed both retrograde and anterograde amnesia. | Saraf et al\(^15\) |
| PSAPP mice | 40 and 160 mg/kg BW | BME reversed both Y-maze and open-field hyperlocomotion behavioral changes in PSAPP mice. Thus, suggested BME reduced Aβ 1-40 and 1-42 levels in the cortex by 60%. | Holcomb et al\(^16\) |
| In vitro model |                  |                         |            |
| PC12 cell line | 100 μg/mL | BME ameliorated the mitochondrial and plasma membrane damage induced by 3 μg/mL scopolamine to 54.83% and 30.30%. | Pandareesh and Anand\(^17\) |
| SK-N-SH cell line | 12.5, 25, 50, 75, and 100 μg/mL | BME pretreatment significantly protects against H₂O₂ and acrolein-induced cytotoxicity and inhibited the generation of intracellular reactive oxygen species in addition to preserving the mitochondrial membrane potential. | Singh et al\(^18\) |
| Primary cortical cultured neurons cell line | 100 μg/mL | BME-protected neurons from β-amyloid-induced cell death. BME inhibited the lipid peroxidation reaction of brain homogenate in a dose-dependent manner. | Limpeanchob et al\(^19\) |
| SH-SY5Y cell line | 0.1 to 25 μM | BME diminished the neurotoxicity of oxidized LDL in a dose-dependent manner potentially by suppression of cellular oxidative stress. | Yamchuen et al\(^20\) |
| SH-SY5Y cell line | Bacoside-A (50 μM) | Bacoamide-A exerted significant inhibitory effects upon cytotoxicity, fibrillation, and particularly membrane interactions of amyloid beta (1-42) | Malishev et al\(^21\) |

Abbreviations: AlCl₃, aluminum chloride; AD, Alzheimer disease; BME, Bacopa monnieri extract; BPC, Bacopaamphospholipid complex; BW, body weight; CAT, catalase; D-Gal, D-galactose; GCLC, glutamate-cysteine ligase catalytic subunit; GSH, glutathione; GST, glutathione S-transferase; GPx, glutathione peroxidase; HO1, heme oxygenase 1; H₂O₂, hydrogen peroxide; ICV-STZ, intracerebroventricular-streptozotocin; IP, intraperitoneal; LDL, low-density lipoprotein; LPO, lipid peroxidation; NaNO₃, sodium nitrate; Nrf2, nuclear factor erythroid 2-related factor 2; OKA, okadaic acid; PLGA, poly-(d, l)-lactide-co-glycolide; PSAPP, presenilin/amyloid precursor protein; SEM, scanning electron microscopy; SOD, superoxide dismutase; DSC, differential scanning calorimetry.
### Table 3. Summary of clinical studies of Bacopa extract in cognition.

| PARTICIPANTS/STUDY DESIGN/GEOGRAPHICAL REGION | INTERVENTION | CLINICAL OUTCOME | REFERENCES |
|---------------------------------------------|--------------|------------------|------------|
| Healthy children, 6-8 years from rural India, Double-blind, randomized placebo-controlled independent group study was employed | One teaspoonful of Bacopa syrup 3 times daily for 3 months. (Each teaspoonful was equivalent to 350 mg of crude Brahmi.) | Strengthened exploratory drive (as measured by maze learning), improved perceptual images of patterns, and increased perceptual organization and reasoning ability (as measured by reaction time) | Sharma et al 82 |
| Healthy adults, between 18 and 60 years, in Swinburne University, Australia. A double-blind, placebo-controlled independent group design in which subjects were randomly allocated to 1 of 2 treatment conditions. | Bacopa extract, 300 mg daily, for 12 weeks | Significant improvement in speed of visual information processing measured by the IT task, learning rate, and memory consolidation measured by the AVLT (P < .05) and state anxiety (P < .01) compared to placebo, with maximal effects evident after 12 weeks. | Stough et al 84 |
| Healthy adults, between the ages of 40 and 65 years in University of Wollongong, Australia. Double-blind, randomized placebo-controlled independent group study was employed | Bacopa extract, 300 mg if subject < 90 kg and 450 mg if > 90 kg, for 12 weeks | Significant effect on a task requiring the retention of new information (P < .05) where the group who received the Brahmi retained more word pairs over the delay than the placebo group. | Roozendaal et al 81 |
| Healthy adults (mean age 73.5 years) in University of Catania, Italy. Double-blind, randomized placebo-controlled clinical trial with a placebo run-in of 6 weeks | Bacopa extract, 300 mg daily, for 12 weeks | Enhanced AVLT delayed word recall memory scores relative to placebo, significant improvement in stroop results (P < .05) and also decreased in CES-D-10 depression scores over time, as well as decreased in combined state plus trait anxiety scores and heart attack. | Calabrese et al 85 |
| Healthy adults, between 18 and 60 years, in Swinburne University, Australia. A double-blind, placebo-controlled independent group design was employed | Bacopa extract, 300 mg daily, for 90 days | Significant improvement in working memory (P = .035), spatial working memory (P = .0510), and significant reduction (P = .029) in the amount of false alarms produced during RVIP task. | Stough et al 86 |
| Children requiring individual educational support, 10.5 years in Center for Research in Mental Retardation (CREMERE), Mumbai, India. The study was conducted as outpatient procedure in hospital settings with close monitoring. | Bacopa extract, 225 mg daily, for 16 weeks | Significant change in the baseline value of working memory and short-term verbal memory from 5.21 ± 0.32 to 6.35 ± 0.25 (P < .05) and 5.33 ± 0.44 to 6.54 ± 0.35 (P < .05). Significant improvement (P < .05) was also seen in logical memory, memory related to personal life and also in visual as well as auditory memory. | Usha et al 85 |
| Ninety eight healthy subjects, age ≥ 55 years in Lismore, New South Wales, Australia. Double-blind, randomized placebo-controlled design was employed | Bacopa extract, 300 mg daily, for 12 weeks | Significantly enhanced the memory acquisition, verbal learning, and delayed recall measure by Rey Auditory Verbal Learning Test (AVLT); Trial a4 (P = .000), Trial a5 (P = .016); Trial a6 (P = .000); Trial a7 (delayed recall, P = .001); Total learning (P = .011) as well retroactive interference (P = .048); Scores including MAC-G, TMT, and CPT improved the group differences and nevertheless were not significant. | 82 |
| Sixty healthy adults, mean age: 62.62 ± 6.46 years (37 females and 23 males) in Thailand. Double-blind, randomized placebo-controlled design was employed | Bacopa extract, 300 mg or 600 mg daily, for 12 weeks | Treated extract group displayed an enhanced working memory as well as a reduction in both P300 and N100 latencies. The plasma AChE activity suppression was also seen, which suggest that it could enhance the cognitive ability and working memory and improve attention. | Peth-Nui et al 86 |
| Seventeen healthy volunteers (13 females and 4 males), mean age 25.23 ± 5.97 in Melbourne, Australia. Double-blind, placebo-controlled cross-over study was employed | Bacopa extract, 320 mg or 640 mg daily, 1 hour and 2 hour | Bacopa consumption showed a change from baseline score indicative of positive cognitive effects at first and second hour post consumption on the Stroop tests as well Letter Search. It produced some nootropic and adaptogenic effects. Positive mod effects and reduction in cortisol levels (physiological stress response) were associated with Bacopa consumption by participants. | Benson et al 85 |
| Sixty healthy adults between 19 and 22 years from Government Medical College, Nagpur, India. Double-blind, randomized placebo-controlled no-crossover, parallel trial was employed | Bacopa extract, 150 mg, for 15 days | Significant improvement in memory test, neuropsychological tests (digit span memory task, paired associate task, logical memory test [story recall], memory span for nonsense syllables) and computerized tests (finger tapping test, simple reaction test, choice reaction test, choice discrimination test, and digit picture substitution test (symbol digit modalities test). Blood biochemistry showed significant elevation in serum calcium levels (still within normal range). | Kumar et al 81 |
| Ten subjects (mean age: 61.88 ± 6.69 years) from Germany with mild cognitive impairment. | Bacopa extract, 500 mg combined with Bacopa extract, 160 and 320 mg | Bacopa extract combined with Bacopa extract indicated better performances in d2-test test onlycontrasted with memory test and arithmetic calculation test (CPT). Quantitative EEG assessment revealed that Bacopa extract combined with Bacopa extract at lower dose (160 mg) increased the spectral power while combined with Bacopa extract at higher dose (320 mg) formed attenuation of all waves except for Delta in frontal-temporal brain areas, indicating massive differences between both extracts. | Dempfl et al 87 |
| Thirty elderly subjects mean age 66 ± 3 years in Bologna, Italy. Double-blind, cross-over designed trial versus placebo group study was employed | Combined nutraceuticals containing Bacopa dry extract (320 mg), algae (100 mg), Crocus sativus (30 mg), copper (2 mg), folate (400 µg), and vitamins of B (450 µg-9 mg) and D (25 µg) | After 2 months of nutraceutical therapy, MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm. Both groups experienced a significant improving in the SRDS scores. | Cicero et al 88 |

Abbreviations: AVLT, Rey Auditory Verbal Learning Test; CESD, Center for Epidemiologic Studies Depression scale; CFT, Complex Figure Test; MAC-Q, Memory Complaint Questionnaire; MMSE, Mini-Mental State Examination; PSQ Index, Perceived Stress Questionnaire; RVIP, Rapid visual information processing; SRDS, Self-Rating Depression Scale; TMT, Trail Making Test.
BME (300 mg/day) for 84 days in participants without dementia aged 65 years and above in University of Catania, Italy also showed improvement in their performance in a restraint recall and Stroop Task, that is, evaluating the capability to bypass unnecessary input. Moreover, in Lismore, New South Wales, Australia, the administration with B monnieri (300 mg/day) in healthy volunteers over 55 years of age showed improvement in their oral learning, memory attainment, and suppressed recall.

In another research done at Swinburne University of Technology, Melbourne, Australia using higher single dose in a double-blind, placebo-controlled trial among normal healthy subjects between the age of 18 and 44 years demonstrated an improved and preserved cognitive ability. Significant enhancement in prompt memory and response performance was also observed when Bacopa in the form of syrup (proportionate to 10 g dried Bacopa daily) was administered in 40 school children aged between 6 and 8 years for 90 days from rural India. The overall clinical trials in humans using BME are summarized in Table 3.

Conclusions

Many traditional plants especially B monnieri have intricate mixtures of chemical compounds, which exhibit various pharmacological and biological activities. They have been used as traditional medicines and for anti-aging. According to the long-established hypothesis, plant compounds are able to maintain the fundamental vitality in the body and have various neuroprotective mechanisms that empower them to be used as part of our well-being. This review reveals the effective use of B monnieri in cognition and neuroprotection and its phytoconstituents that can be used in novel drug discovery.

Author Contributions

ASAM, SV and PM designed the flow and wrote sub-sections of the manuscript. All the other authors contributed to manuscript revision, proof reading and approval of the submitted version.

ORCID iD

Priya Madhavan

https://orcid.org/0000-0001-6714-1279

REFERENCES

1. Jadadap R. Review of Alzheimer’s disease treatment and potential future therapies. Annu Rev Chang Healthc. 2018;2.
2. Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2007;104:1189–1191.
3. Singh M, Murthy V, Ramassamy C. Modulation of hydrogen peroxide and acros-tein-induced oxidative stress, mitochondrial dysfunctions and redox regulated pathways by the Bacopa monniera extract: potential implication in Alzheimer’s disease. J Neuroimmune. 2007;18:49–59.
4. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neurosurg Rev. 2008;31:295–305.
5. Pardridge WM. Blood-brain barrier biology and methodology. J Neurosci. 2005;25:111–120.
6. Chakravarty AK, Sarkar T, Manndra K, Nakane T, Kawahara N. Bacopasaponin mixture bacoside A in Bacopa monniera by HPLC. Phytomedicine. 2005;12:864.
7. Rauf K, Subhan F, Al-Othman A, Khan J, Zarelli A, Shah M. Preclinical profile of bacopasides from Bacopa monniera (BM) as an emerging class of therapeuti-cism in the treatment of people with cognitive impairment. Curr Med Chem. 2013;20:1028–1037.
8. Deepak M, Amit A. The need for establishing identities of “bacoside A and B,” the putative major bioactive saponins of Indian medicinal plant Bacopa monniera. Phytotherapy. 2004;11:264–268.
9. Kapoor R, Srivastava S, Kakkar P. Bacopa monniera modulates antioxidant responses in brain and kidney of diabetic rats. Environ Toxicol Pharmacol. 2009;27:62–69.
10. Deepak M, Sangh G, Arun P, Amit A. Quantitative determination of the major saponin mixture bacoside A in Bacopa monniera by HPLC. Phytomental. 2005;16:24–29.
11. Saraf MK, Prabhakar S, Khanda J, Anand A. Bacopamodiol attenuates scopodamine-induced impairment of spatial memory in mice. Evid Based Complement Altern Med. 2011;2011:236186.
12. Mukherjee S, Dugad S, Bhandare R, et al. Evaluation of comparative free-radi-cal quenching potential of Brahmi (Bacopa monniera) and Mandomarpuri (Cen-tella asiatica). Ayu. 2011;32:258–264.
13. Hockom LA, Dhanaeekaran M, Hirt AR, Young KA, Riggs M, Manyam BV. Bacopasaponin mixture reduces amyloid levels in PSAPP mice. J Alzheimers Dis. 2006;9:243–251.
14. Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K. Neuroprotective effect of Bacopa monniera on beta-amidloid-induced cell death in primary cortical cultures. J Ethnopharmacol. 2008;120:112–117.
15. Tajjan KE, Prabath J, Singh HK. Molecular and functional characterization of Bacopa monniera: a retrospective review. Evid Based Complement Altern Med. 2014;2015:945217.
16. De K, Chandra S, Misra M. Evaluation of the biological effect of brahmi (Bacopa monniera Linn) extract on the biodistribution of technetium-99m radiopharma-ceuticals. Life Sci J. 2008;5:45–49.
17. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev. 1997;27:161–170.
18. Singh R, Panduri J, Kumar D, et al. Evaluation of memory enhancing clinically available standardised extract of Bacopa monniera on P-glycoprotein and cytochrome P450 3A in Sprague-Dawley rats. Planta Med. 2013;8:72517.
19. Barbhaiya H, Desai R, Saxena V, et al. Efficacy and tolerability of BacoMind in elderly: a randomized, double-blind, placebo-controlled trial. J Alzheimers Dis. 2013;8:e72517.
20. Stough C, Scholey A, Cropley V, et al. Examining the cognitive effects of a spe-cific extract of Bacopa monniera (CDB108: Keenmnd): a review of ten years of research at Swinburne University. J Pharm Pharm Sci. 2013;16:254–258.
21. Benson S, Downey LA, Stough C, Wetherell M, Zangara A, Scholey A. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg
of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014;28:551–559.
36. Downey LA, Kean J, Nemeń F, et al. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res. 2012;27:1407–1413.
37. Preethi J, Singh HK, Rajan KE. Possible involvement of standardized Bacopa monniera extract (CDRI-08) in epigenetic regulation of reelin and brain-derived neurotrophic factor to enhance memory. Front Pharmacol. 2016;7:166.
38. Rai R, Singh HK, Prasad S. A special extract of Bacopa monnieri (CDRI-08) restores learning and memory by upregulating expression of the NMDA receptor subunit GluN2B in the brain of scopolamine-induced amnesic mice. Eur Biol Complex Complement Altern Med. 2015;2015:254303.
39. Goswami S, Saqi A, Kumar N, Thawani T, Mawani M. Effect of Bacopa monnieri on cognitive functions in Alzheimer’s disease patients. Int J Nat Med Sci Publ Health. 2011;3:283–293.
40. Hingorani L, Patel S, Ebersole B. Sustained cognitive effects and safety of HPLC-standardized Bacopa monnieri extract: a randomized, placebo controlled clinical trial. Planta Medica. 2012;78:PH122.
41. Kumar N, Abichandani L, Thawani T, Gharpure K, Mavit Ramana G. Efficacy of standardized extract of Bacopa monnieri (Bacogreen®) on cognitive functions of medical students: a six-week, randomized placebo-controlled trial. Evid Based Complement Alternat Med. 2016;2016:403423.
42. Thakkar VT, Deshmukh A, Hingorani L, et al. Development and optimization of dispersible tablet of Bacopa monnieri with improved functionality for memory enhancement. J Pharm Biol Sci. 2017;9:208–215.
43. Malishev R, Shaim-Nw S, Nandi S, Kolusheva S, Gazit E, Jelinek R. Bacoside-A, an Indian traditional medicine substance, inhibits β-amylloid cytotoxicity, fibillation, and membrane interactions. ACS Chem Neurosci. 2017;8:884–891.
44. Farooqui AA, Farooqui T. Contribution of diabetes and metabolic syndrome in the pathogenesis of Alzheimer’s disease. In: Farooqui, A, Farooqui, AA, eds. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018;14:1–15.
45. Mohanaran S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar M. Mitochondrial dysfunction and the role of Mitophagy in Alzheimer’s disease but not frontotemporal dementia. Life Sci. 2014;63:29–35.
46. Rastogi M, Ojha RP, Prabu P, Devi BP, Agrawal A, Dubey G. Prevention of dispersible tablet of Bacopa monnieri with improved functionality for memory enhancement. J Pharm Bioallied Sci. 2017;9:208–215.
47. Thippeswamy AH, Rafiq M, Vaswathna GL, Kayva KJ, Antiluralkid SR, Patki PS. Evaluation of Bacopa monniera for its synergistic activity with rivastigmine in reversing aluminum-induced memory loss and learning deficit in rats. J Acupunct Meridian Stud. 2011;6:208–213.
48. Dai M, Shanker G, Nath C, Pal R, Singh S, Singh HK. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anti-cholinesterase and cognitive enhancing activities. Pharmacia Biomed Behav. 2002;73:893–900.
49. Uabundit N, Wutanathan J, Micumapara S, Inginankian K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease model. J Ethnopharmacol. 2010;127:26–31.
50. Jyoti A, Sethi P, Sharma D. Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain. J Ethnopharmacol. 2007;115:56–62.
51. Khan MB, Ahmad M, Ahmad S, et al. Bacopa monniera ameliorates cognitive impairment and neurodegeneration induced by intracerebroventricular-streptozotocin in rat: behavioral, biochemical, immunohistochemical and histopathological evidences. Metab Brain Dis. 2015;30:115–127.
52. Kunte KR, Kuna Y. Neuroprotective effect of Bacopa monniera on memory defici- cits and ATPxase system in Alzheimer’s disease (AD) induced mice. Sci Innov Res. 2018;5:1–22.
53. Dwivedi S, Nagarajan R, Hanif K, Siddiqui IH, Nath C, Shukla R. Standardized extract of Bacopa monniera attenuates okadaic acid induced memory dysfunction in rats: effect on Nr1f2 pathway. Evid Based Complement Alternat Med. 2020;2020:1506913.
54. Rastogi M, Ohja RP, Prabu P, Devi BP, Agrawal A, Dubey G. Prevention of age-associated neurodegeneration and promotion of healthy brain ageing in female Wistar rats by long term use of bacoside. Biogerontology. 2012;13:183–195.
55. Jose S, Sonwya S, Cunin T, Aleykutty N, Thomas S, Souto E. Surface modified PLGA nanoparticles for brain targeting of Bacoside-A. Eur J Pharm Sci. 2014;63:29–35.
56. Pandaresh M, Anand T. Neuroromulatory propensity of Bacopa monniera against scopolamine-induced cytotoxicity in PC12 cells via down-regulation of AChE and up-regulation of BDNF and muscarinic-1 receptor expression. Cell Mol Neurobiol. 2013;33:875–884.
57. Yamchun M, Chaiwiang N, Lappanachayakol P, Inginankian K, Limpeanoch N. Neuroprotective effect of Bacopa Monnieri extract on oxidized low density lipoprotein-induced neurotoxicity in SH-SY5Y neuroblastoma cells. Thai J Physiol Pharmacol. 2015;12:183–196.
58. Habib P, Madanagudi S, Kulkarni R, Jadav S, Vanakudri R, Kulkarni V. Prepara- tion and evaluation of Bacopa–phospholipid complex for antiannemic activity in rodents. Drug Invention Today. 2013;5:13–21.
59. Dimpfel W, Schombert I, Biller A. Psychophysiological effects of Sidetirs and Bacopa extract and three combinations thereof—a quantitative EEG study in subjects suffering from mild cognitive impairment (MCI). Advances in Alzheim- er’s Disease. 2016;5:1–22.
60. Stough C, Downey LA, Lloyd J, et al. Examining the nootropic effects of a spe- cial extract of Bacopa monniera on human cognitive functioning: 90-day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22:1629–1634.
61. Roddrenys S, Booth D, Bulzomi S, Phipps A, Micallief C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacol- ogy. 2002;27:279–281.
82. Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo–controlled, double-blind trial. *J Altern Complement Med*. 2010;16:753–759.

83. Sharma R, Chaturvedi C, Tewari P. Efficacy of Bacopa monniera in revitalizing intellectual functions in children. *J Res Edu Ind Med*. 1987;1:12.

84. Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. *Psychopharmacology*. 2001;156:481–484.

85. Usha P, Wasim P, Joshua J, et al. BacoMind*: a cognitive enhancer in children requiring individual education programme. *J Pharmucol Toxicol*. 2008;3:302–310.

86. Peth-Nui T, Wattanathorn J, Muchimapura S, et al. Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. *Evid Based Complement Alternat Med*. 2012, 2012:606424.
Author/s:
Manap, ASA; Vijayabalan, S; Madhavan, P; Chia, YY; Arya, A; Wong, EH; Rizwan, F; Bindal, U; Koshy, S

Title:
Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies

Date:
2019-07-31

Citation:
Manap, A. S. A., Vijayabalan, S., Madhavan, P., Chia, Y. Y., Arya, A., Wong, E. H., Rizwan, F., Bindal, U. & Koshy, S. (2019). Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies. DRUG TARGET INSIGHTS, 13, https://doi.org/10.1177/1177392819866412.

Persistent Link:
http://hdl.handle.net/11343/245115

File Description:
published version

License:
CC BY-NC